文献速递主动脉疾病

胸主动脉腔内修复术中支架放大率对无并发症B型主动脉夹层长期结局的影响:单中心回顾性研究

The Impact of Oversizing in Thoracic Endovascular Aortic Repair on Long-Term Outcomes in Uncomplicated Type B Aortic Dissection: A Single-Center Retrospective Study.
PubMed 文献 · J Endovasc Ther · 2023-04-20

该单中心回顾性研究纳入2010年1月至2018年12月226例接受胸主动脉腔内修复术(TEVAR)的无并发症B型主动脉夹层(TBAD)患者,按支架放大率分为≤5%组(n=153)和>5%组(n=73)。两组5年全因死亡率和主动脉相关死亡率无显著差异,但>5%组逆性A型主动脉夹层(RTAD)累积发生率显著更高(p=0.007),且均发生在TEVAR术后1年内。作者认为≤5%可能是无并发症TBAD行TEVAR的合适放大率。

要点

  • >5%放大率组5年RTAD累积发生率为6.9%,显著高于≤5%组的0.7%(p=0.007)。
  • 两组5年全因死亡率(93.3% vs 92.3%,p=0.957)和主动脉相关死亡率(95.0% vs 96.7%,p=0.928)无显著差异。
  • 所有RTAD均发生在TEVAR术后1年内。

核心结论

  • ≤5%与>5%放大率组5年全因死亡率和主动脉相关死亡率无显著差异。
  • >5%放大率与TEVAR术后1年内RTAD风险增加相关,作者认为≤5%可能是无并发症TBAD行TEVAR的合适放大率。

研究设计与样本

  • 单中心回顾性研究,纳入2010年1月至2018年12月226例无并发症TBAD接受TEVAR的患者,分为≤5%放大率组(n=153)和>5%放大率组(n=73)。
  • 主要终点为全因死亡率和主动脉相关死亡率,次要终点为手术相关并发症(RTAD、内漏、远端支架诱导新发破口(SINE)和晚期再干预)。
  • 全因死亡率和主动脉相关死亡率采用Kaplan-Meier生存分析,手术相关并发症采用以全因死亡为竞争风险的竞争风险模型评估。

主要发现

  • ≤5%组平均放大率为2.1%±1.5%,>5%组为9.6%±4.1%。
  • 两组30天死亡率和不良事件差异无统计学意义。
  • ≤5%组与>5%组5年全因死亡率无显著差异(≤5%组93.3% vs >5%组92.3%,p=0.957)。
  • ≤5%组与>5%组5年主动脉相关死亡率无显著差异(≤5%组95.0% vs >5%组96.7%,p=0.928)。
  • >5%组5年RTAD累积发生率显著高于≤5%组(>5%组6.9% vs ≤5%组0.7%,p=0.007),所有RTAD均发生在TEVAR术后1年内。

关键数值与推荐

  • 5年全因死亡率:≤5%组93.3% vs >5%组92.3%(p=0.957)。
  • 5年主动脉相关死亡率:≤5%组95.0% vs >5%组96.7%(p=0.928)。
  • 5年RTAD累积发生率:>5%组6.9% vs ≤5%组0.7%(p=0.007)。
  • 两组5年I型内漏、远端SINE和晚期再干预累积发生率差异无统计学意义。

临床怎么用

  • 作者认为,对于无并发症TBAD患者,选择≤5%放大率有利于降低术后RTAD风险,为支架尺寸选择提供依据。
  • 作者指出,TEVAR术后1年内是发生RTAD的主要时间段,应重视该时期的管理和随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to assess the impact of oversizing in thoracic endovascular aortic repair (TEVAR) on early and long-term survival and major adverse events in patients with uncomplicated type B aortic dissection (TBAD). METHODS: Between January 2010 and December 2018, 226 patients who were diagnosed with uncomplicated TBAD and received TEVAR were analyzed retrospectively. The patients were divided into ≤5% oversizing (n=153) and >5% oversizing (n=73) groups. Primary end points were all-cause and aortic-related mortalities. Secondary end points were procedure-related complications, including retrograde type A aortic dissection (RTAD), endoleak, distal stent-induced new entry (SINE), and late reintervention. All-cause and aortic-related mortalities were assessed using the Kaplan-Meier survival method, while procedure-related complications were evaluated using a competing risk model with all-cause death as a competing risk. RESULTS: Mean oversizing was 2.1%±1.5% in the ≤5% oversizing group and 9.6%±4.1% in the >5% oversizing group. Differences in the 30-day mortality and adverse events between the 2 groups were statistically insignificant. The freedom from all-cause mortality was comparable between the ≤5% oversizing group and the >5% oversizing group (≤5%: 93.3% at 5 years, >5%: 92.3% at 5 years, p=0.957). No significant difference was observed between both groups in the freedom from aortic-related mortality (≤5%: 95.0% at 5 years, >5%: 96.7% at 5 years, p=0.928). However, the competing risk analyses revealed that the cumulative incidence of RTAD was statistically significantly greater in the >5% oversizing group than in the ≤5% oversizing group (≤5%: 1(0.7%) at 5 years, >5%: 6(6.9%) at 5 years, p=0.007). All RTADs occurred within a year of TEVAR. The differences in the cumulative incidences of type I endoleak, distal SINE, and late reintervention were not significant between the 2 groups. CONCLUSION: The differences in the 5-year all-cause mortality and aortic-related mortality between patients with uncomplicated TBAD who received TEVAR with ≤5% oversizing and those who got TEVAR with >5% oversizing were insignificant. However, oversizing >5% was considerably associated with an increased risk of RTAD within a year of TEVAR, suggesting that oversizing ≤5% may be the appropriate size for TEVAR in patients with uncomplicated TBAD. CLINICAL IMPACT: For patients with uncomplicated TBAD, choosing oversizing ≤5% in endovascular treatment is beneficial to reduce the risk of postoperative retrograde type A aortic dissection. This finding provides a basis for stent size selection in endovascular repair. In addition, one year after TEVAR is the main time period for postoperative retrograde type A aortic dissection, and attention should be paid to the management and follow-up of this period.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Xiang D, Chai B, Huang J, et al. The Impact of Oversizing in Thoracic Endovascular Aortic Repair on Long-Term Outcomes in Uncomplicated Type B Aortic Dissection: A Single-Center Retrospective Study. J Endovasc Ther. 2023. PMID: 37078474. doi:10.1177/15266028231166282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。